<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233232</url>
  </required_header>
  <id_info>
    <org_study_id>D3550C00002</org_study_id>
    <secondary_id>2010-021217-23</secondary_id>
    <nct_id>NCT01233232</nct_id>
  </id_info>
  <brief_title>A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>CIRRUS</acronym>
  <official_title>A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients
      with Chronic Obstructive Pulmonary Disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Who Experienced at Least One Adverse Events(s)</measure>
    <time_frame>From start of treatment (Day 0) up to 28 days (End of Treatment)</time_frame>
    <description>Adverse event (AE) data, both serious and non-serious. An AE is the development of an undesirable medical condition (eg, nausea, chest pain, tachycardia, laboratory findings) or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Physical Examination Findings</measure>
    <time_frame>Last Observation on Treatment (up to Day 28)</time_frame>
    <description>Physical examination includes assessment of general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, musculo-skeletal (including spine and extremities), cardiovascular, lungs and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>ECGs were recorded in the supine position after the patient has rested for 10 minutes. Heart rate, QRS duration, PR, RR and QT intervals were recorded. Overall evaluation of the ECG is classified as normal, abnormal or borderline. Only participants with ECG at baseline classified as normal are reported (ie, only changes from normal to abnormal).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for Leucocytes Count in Blood (Safety Blood Sample)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in circulating leucocyte counts (including neutrophils) is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for Body Temperature</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in body temperature (oral) is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for Systolic Blood Preassure (Vital Signs)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in systolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for Diastolic Blood Pressure (Vital Signs)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in diastolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for Pulse Rate (Vital Signs)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in pulse rate (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for FEV1 Pre-bronchodilator (Lung Function Test)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in FEV1 Pre-bronchodilator is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for FEV1 Post-bronchodilator (Lung Function Test)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in FEV1 Post-bronchodilator is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Developed High Transaminase Values (Clinical Chemistry)</measure>
    <time_frame>Up to Follow-up Visit (3 to 18 days after End of Treatment [Day 28])</time_frame>
    <description>High Transaminase Values are defined as a measurment of ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than or equal to 3 times the upper limit of normal (ALT ULN = 36 IU/L, AST ULN = 33 IU/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment for Total Protein (Urinalysis)</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
    <description>The change in total protein in urine is calculated as the End of Treatment value minus the Baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of AZD5069 After 1 Hour of Dosing</measure>
    <time_frame>End of Treatment (Day 28), 1 hour after dosing</time_frame>
    <description>At this visit, approximately 1 hour after dosing (at the clinic), a blood sample was collected for determination of drug concentration in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve of AZD5069</measure>
    <time_frame>End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing</time_frame>
    <description>The area under the plasma concentration curve is estimated from time 0 (dosing) to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration for AZD5069</measure>
    <time_frame>End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing</time_frame>
    <description>The maximum plasma concentration (Cmax) is the highest level of drug in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration for AZD5069</measure>
    <time_frame>End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing</time_frame>
    <description>Time (in relation to dosing) at which the maximum plasma concentration is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Reduction of Circulating Neutrophils in Blood, From Baseline</measure>
    <time_frame>Baseline (last non-missing assessment prior to first dose of study medication), weeks 1, 2 and 3, and End of Treatment (Day 28)</time_frame>
    <description>The change in circulating neutrophils in blood is calculated as the visit value minus the Baseline value. Only participants with reduction are considered.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Laymen Terminology Chronic Bronchitis and Emphysema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm AZD5069 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm AZD5069 80mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose bid</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5069 50mg</intervention_name>
    <description>Oral dose bid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5069 80mg</intervention_name>
    <description>Oral dose bid</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of COPD with symptoms for more than one year before screening

          -  Body mass index of 18-30 kg/m2 and weight of 50-100kg

          -  Current or ex-smokers with a smoking history of at least 10 pack years (1 pack year =
             tobacco consumption corresponding to 20 cigarettes smoked per day for one year) at
             screening

          -  FEV1 of 30% or above and less than 80% of the predicted normal value
             post-bronchodilator at screening

          -  FEV1/FVC less than 70% post-bronchodilator at screening

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Exacerbation of COPD which was not resolved within 30 days of first dosing

          -  Patients who have received live or live-attenuated vaccine in the 2 weeks prior to
             first dosing

          -  Asthma and any current respiratory tract disorder other than COPD which is considered
             to be clinically significant

          -  Disease history suggesting reduced or abnormal immune function other than that related
             to COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GROßHANSDORF</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Százhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=208&amp;filename=D3550C00002_Revised_Clinical_Study_Protocol.pdf</url>
    <description>D3550C00002_Revised_Clinical_Study_Protocol.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=208&amp;filename=D3550C00002_Study_Synopsis.pdf</url>
    <description>D3550C00002_Study_Synopsis.pdf</description>
  </link>
  <reference>
    <citation>Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.</citation>
    <PMID>25681277</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <results_first_submitted>April 30, 2015</results_first_submitted>
  <results_first_submitted_qc>April 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2015</results_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease, Neutrophil, Respiratory Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 22 November 2010. Last patient completed: 22 March 2011. Fifteen centres across 4 countries participated in this study: Bulgaria (4), Germany (4), Hungary (4) and Ukraine (3)</recruitment_details>
      <pre_assignment_details>22 patients enrolled were not randomized due to eligibility not fulfilled (17 patients) and voluntary discontinuation (5 patients)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>4 x placebo capsules, twice daily (bid)</description>
        </group>
        <group group_id="P2">
          <title>AZD5069 50 mg</title>
          <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
        </group>
        <group group_id="P3">
          <title>AZD5069 80 mg</title>
          <description>4 x 20 AZD5069 mg capsules, bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Voluntary Discontinuation by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>4 x placebo capsules, twice daily (bid)</description>
        </group>
        <group group_id="B2">
          <title>AZD5069 50 mg</title>
          <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
        </group>
        <group group_id="B3">
          <title>AZD5069 80 mg</title>
          <description>4 x 20 AZD5069 mg capsules, bid</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="7.9"/>
                    <measurement group_id="B2" value="65" spread="6.9"/>
                    <measurement group_id="B3" value="65" spread="7.4"/>
                    <measurement group_id="B4" value="64" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.842" spread="2.77"/>
                    <measurement group_id="B2" value="27.645" spread="2.89"/>
                    <measurement group_id="B3" value="25.803" spread="3.18"/>
                    <measurement group_id="B4" value="26.118" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.7" spread="14.02"/>
                    <measurement group_id="B2" value="78.9" spread="9.18"/>
                    <measurement group_id="B3" value="75.4" spread="10.90"/>
                    <measurement group_id="B4" value="76" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% Predicted FEV1 at screening</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="13.9"/>
                    <measurement group_id="B2" value="57" spread="13.6"/>
                    <measurement group_id="B3" value="54" spread="12.1"/>
                    <measurement group_id="B4" value="56" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC at screening</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.54" spread="9.62"/>
                    <measurement group_id="B2" value="51.75" spread="11.65"/>
                    <measurement group_id="B3" value="54.52" spread="10.51"/>
                    <measurement group_id="B4" value="52.91" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nicotine pack years</title>
          <description>one pack year= 1 pack (20 cigrettes) per day for 1 year, or equivalent</description>
          <units>Pack Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="21.4"/>
                    <measurement group_id="B2" value="39" spread="22"/>
                    <measurement group_id="B3" value="34" spread="17.9"/>
                    <measurement group_id="B4" value="37" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GOLD classification</title>
          <description>The spirometric classification of severity COPD now includes four stages: Stage I: Mild; Stage II: Moderate; Stage III: Severe; Stage IV: Very Severe.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>II Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Who Experienced at Least One Adverse Events(s)</title>
        <description>Adverse event (AE) data, both serious and non-serious. An AE is the development of an undesirable medical condition (eg, nausea, chest pain, tachycardia, laboratory findings) or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.</description>
        <time_frame>From start of treatment (Day 0) up to 28 days (End of Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Experienced at Least One Adverse Events(s)</title>
          <description>Adverse event (AE) data, both serious and non-serious. An AE is the development of an undesirable medical condition (eg, nausea, chest pain, tachycardia, laboratory findings) or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Physical Examination Findings</title>
        <description>Physical examination includes assessment of general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, musculo-skeletal (including spine and extremities), cardiovascular, lungs and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.</description>
        <time_frame>Last Observation on Treatment (up to Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Physical Examination Findings</title>
          <description>Physical examination includes assessment of general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, musculo-skeletal (including spine and extremities), cardiovascular, lungs and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG)</title>
        <description>ECGs were recorded in the supine position after the patient has rested for 10 minutes. Heart rate, QRS duration, PR, RR and QT intervals were recorded. Overall evaluation of the ECG is classified as normal, abnormal or borderline. Only participants with ECG at baseline classified as normal are reported (ie, only changes from normal to abnormal).</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG)</title>
          <description>ECGs were recorded in the supine position after the patient has rested for 10 minutes. Heart rate, QRS duration, PR, RR and QT intervals were recorded. Overall evaluation of the ECG is classified as normal, abnormal or borderline. Only participants with ECG at baseline classified as normal are reported (ie, only changes from normal to abnormal).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for Leucocytes Count in Blood (Safety Blood Sample)</title>
        <description>The change in circulating leucocyte counts (including neutrophils) is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for Leucocytes Count in Blood (Safety Blood Sample)</title>
          <description>The change in circulating leucocyte counts (including neutrophils) is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>10^9/L cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="1.974"/>
                    <measurement group_id="O2" value="-1.55" spread="2.059"/>
                    <measurement group_id="O3" value="-1.08" spread="2.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for Body Temperature</title>
        <description>The change in body temperature (oral) is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for Body Temperature</title>
          <description>The change in body temperature (oral) is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>degrees C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.43"/>
                    <measurement group_id="O2" value="0.0" spread="0.57"/>
                    <measurement group_id="O3" value="-0.0" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for Systolic Blood Preassure (Vital Signs)</title>
        <description>The change in systolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for Systolic Blood Preassure (Vital Signs)</title>
          <description>The change in systolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="11.0"/>
                    <measurement group_id="O2" value="-0.0" spread="12.1"/>
                    <measurement group_id="O3" value="-3.0" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for Diastolic Blood Pressure (Vital Signs)</title>
        <description>The change in diastolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for Diastolic Blood Pressure (Vital Signs)</title>
          <description>The change in diastolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="7.2"/>
                    <measurement group_id="O2" value="-2.0" spread="7.9"/>
                    <measurement group_id="O3" value="-1.0" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for Pulse Rate (Vital Signs)</title>
        <description>The change in pulse rate (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for Pulse Rate (Vital Signs)</title>
          <description>The change in pulse rate (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="6.2"/>
                    <measurement group_id="O2" value="-1" spread="6.9"/>
                    <measurement group_id="O3" value="3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for FEV1 Pre-bronchodilator (Lung Function Test)</title>
        <description>The change in FEV1 Pre-bronchodilator is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for FEV1 Pre-bronchodilator (Lung Function Test)</title>
          <description>The change in FEV1 Pre-bronchodilator is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.238"/>
                    <measurement group_id="O2" value="0.05" spread="0.238"/>
                    <measurement group_id="O3" value="-0.01" spread="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for FEV1 Post-bronchodilator (Lung Function Test)</title>
        <description>The change in FEV1 Post-bronchodilator is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for FEV1 Post-bronchodilator (Lung Function Test)</title>
          <description>The change in FEV1 Post-bronchodilator is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.230"/>
                    <measurement group_id="O2" value="0.10" spread="0.256"/>
                    <measurement group_id="O3" value="0.02" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed High Transaminase Values (Clinical Chemistry)</title>
        <description>High Transaminase Values are defined as a measurment of ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than or equal to 3 times the upper limit of normal (ALT ULN = 36 IU/L, AST ULN = 33 IU/L).</description>
        <time_frame>Up to Follow-up Visit (3 to 18 days after End of Treatment [Day 28])</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed High Transaminase Values (Clinical Chemistry)</title>
          <description>High Transaminase Values are defined as a measurment of ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than or equal to 3 times the upper limit of normal (ALT ULN = 36 IU/L, AST ULN = 33 IU/L).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment for Total Protein (Urinalysis)</title>
        <description>The change in total protein in urine is calculated as the End of Treatment value minus the Baseline value.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment for Total Protein (Urinalysis)</title>
          <description>The change in total protein in urine is calculated as the End of Treatment value minus the Baseline value.</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.034"/>
                    <measurement group_id="O2" value="-0.01" spread="0.022"/>
                    <measurement group_id="O3" value="-0.01">Only one value in arm 3. SD is not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of AZD5069 After 1 Hour of Dosing</title>
        <description>At this visit, approximately 1 hour after dosing (at the clinic), a blood sample was collected for determination of drug concentration in plasma.</description>
        <time_frame>End of Treatment (Day 28), 1 hour after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of AZD5069 After 1 Hour of Dosing</title>
          <description>At this visit, approximately 1 hour after dosing (at the clinic), a blood sample was collected for determination of drug concentration in plasma.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2599.551" spread="2085.601"/>
                    <measurement group_id="O3" value="5433.611" spread="4622.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve of AZD5069</title>
        <description>The area under the plasma concentration curve is estimated from time 0 (dosing) to 24 hours after dosing.</description>
        <time_frame>End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O2">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve of AZD5069</title>
          <description>The area under the plasma concentration curve is estimated from time 0 (dosing) to 24 hours after dosing.</description>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29600" spread="108" lower_limit="4270" upper_limit="136000"/>
                    <measurement group_id="O2" value="38800" spread="95.6" lower_limit="6700" upper_limit="143000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration for AZD5069</title>
        <description>The maximum plasma concentration (Cmax) is the highest level of drug in plasma.</description>
        <time_frame>End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O2">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration for AZD5069</title>
          <description>The maximum plasma concentration (Cmax) is the highest level of drug in plasma.</description>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2550" spread="107" lower_limit="367" upper_limit="11700"/>
                    <measurement group_id="O2" value="3340" spread="95.6" lower_limit="576" upper_limit="12300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration for AZD5069</title>
        <description>Time (in relation to dosing) at which the maximum plasma concentration is observed.</description>
        <time_frame>End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O2">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration for AZD5069</title>
          <description>Time (in relation to dosing) at which the maximum plasma concentration is observed.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" lower_limit="1.56" upper_limit="1.56"/>
                    <measurement group_id="O2" value="1.56" lower_limit="1.56" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Reduction of Circulating Neutrophils in Blood, From Baseline</title>
        <description>The change in circulating neutrophils in blood is calculated as the visit value minus the Baseline value. Only participants with reduction are considered.</description>
        <time_frame>Baseline (last non-missing assessment prior to first dose of study medication), weeks 1, 2 and 3, and End of Treatment (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Placebo</title>
            <description>4 x placebo capsules, twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD5069 50 mg</title>
            <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD5069 80 mg</title>
            <description>4 x 20 AZD5069 mg capsules, bid</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Reduction of Circulating Neutrophils in Blood, From Baseline</title>
          <description>The change in circulating neutrophils in blood is calculated as the visit value minus the Baseline value. Only participants with reduction are considered.</description>
          <units>10^9/L cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.324" spread="1.2152"/>
                    <measurement group_id="O2" value="2.759" spread="1.4422"/>
                    <measurement group_id="O3" value="2.678" spread="2.0710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>4 x placebo capsules, twice daily (bid)</description>
        </group>
        <group group_id="E2">
          <title>AZD5069 50 mg</title>
          <description>1 x 50 mg AZD5069 capsule and 3 x placebo capsules, bid</description>
        </group>
        <group group_id="E3">
          <title>AZD5069 80 mg</title>
          <description>4 x 20 AZD5069 mg capsules, bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

